NPPA Fixes Retail Price Of 37 Formulations, Details
New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA) has fixed the retail price of the 37 formulations under the Drugs (Prices Control) Order.
This price fixation is followed by decisions made by the National Pharmaceuticals Pricing Authority (NPPA) at its 128th Authority Metting dated on 10th May 2024.
The list includes Akums Drugs and Pharmaceuticals, Abbott Healthcare's Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets, Mascot Health Series, Renon Healthcare's Dapagliflozin, Metformin Hydrochloride and Glimepiride Tablets, Mascot Health Series, Primus Remedies' Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets.
The list further includes Pure and Cure Healthcare, Torrent Pharmaceuticals' Telmisartan, Amlodipine, Hydrochlorothiazide Tablets, Akums Drugs and Pharmaceuticals, Sun Pharmaceuticals Industries' Bilastine and Montelukast oral suspension, Intas Pharmaceuticals' Antacid Antigas gel, Innova Captab, Dr. Reddy's Laboratories' Cefixime and Ofloxacin Oral suspension and etc.
This came exercise of the powers conferred by paragraphs 5, 11, and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013 and S. O. 5249(E) dated 11th November 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (NPPA), has fixed, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said table with the strength, unit and name of manufacturer and marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
Sl. No. | Medicines | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
1 | Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets | Each film-coated bilayered Tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 1000mg (As Extended release) Glimepiride IP 1 mg | 1 Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s La Renon Healthcare Pvt. Ltd. | 14.75 |
2 | Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets | Each film-coated bilayered Tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 1000mg (As Extended release) Glimepiride IP 1 mg | 1 Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Primus Remedies Pvt. Ltd. | 14.53 |
3 | Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets | Each film-coated bilayered Tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 1000mg (As Extended release) Glimepiride IP 1 mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Abbott Healthcare Pvt. Ltd. | 14.75 |
4 | Dapagliflozin, Metformin Hydrochloride (Extended | Each film-coated bilayered Tablet contains: | 1 Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s La Renon | 16.00 |
Sl. No. | Medicines | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Release) and Glimepiride Tablets | Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 1000mg (As Extended release) Glimepiride IP 2 mg | Healthcare Pvt. Ltd. | |||
5 | Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets | Each film-coated bilayered Tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 1000mg (As Extended release) Glimepiride IP 2 mg | 1 Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Primus Remedies Pvt. Ltd. | 16.24 |
6 | Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets | Each film-coated bilayered Tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 1000mg (As Extended release) Glimepiride IP 2 mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Abbott Healthcare Pvt. Ltd. | 16.43 |
7 | Sitagliptin Phosphate, Metformin Hydrochloride, and Glimepiride Tablets | Each film coated Tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg Glimepiride IP 1 mg | 1 Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Aristo Pharmaceuticals Pvt. Ltd. | 13.35 |
8 | Sitagliptin Phosphate, Metformin Hydrochloride and Glimepiride Tablets | Each film coated Tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg Glimepiride IP 2 mg | 1 Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Aristo Pharmaceuticals Pvt. Ltd. | 15.03 |
9 | Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets | Each film coated bilayered Tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 500mg (As Extended release) Glimepiride IP 1 mg | 1 Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Primus Remedies Pvt. Ltd. | 13.24 |
10 | Dapagliflozin, Metformin Hydrochloride | Each film coated bilayered Tablet contains: Dapagliflozin Propanediol | 1 Tablet | M/s Mascot Health Series Pvt. Ltd. / | 14.83 |
Sl. No. | Medicines | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
(Extended Release) and Glimepiride Tablets | USP eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 500mg (As Extended release) Glimepiride IP 2 mg | M/s Primus Remedies Pvt. Ltd. | |||
11 | Diclofenac Diethylamine, Methyl Salicylate, Virgin Linseed Oil & Menthol Topical spray | Composition: Diclofenac Diethylamine IP 1.16% w/w eq. to Diclofenac Sodium 1.00% w/w, Methyl Salicylate IP 10.00% w/w, Virgin Linseed Oil BP 3.0% w/w, Menthol IP 5.00% w/w | 1 gm | M/s Pontika Aerotech Limited / M/s Unison Pharmaceuticals Pvt. Ltd. | 2.73 |
12 | Povidone-Iodine & Ornidazole Ointment | Composition: Povidone-Iodine IP 5%w/w (Available Iodine 0.5%w/w) Ornidazole IP 1% w/w in an Ointment base | 1 gm | M/s Curetech Skincare / M/s J.B. Chemicals & Pharmaceuticals Ltd. | 4.11 |
13 | Bisoprolol Fumarate and Telmisartan Tablets | Each film coated Tablet contains: Bisoprolol Fumarate IP 5 mg Telmisartan IP 40 mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt Ltd / M/s J.B. Chemicals & Pharmaceuticals Ltd. | 11.21 |
14 | Bisoprolol Fumarate and Telmisartan Tablets | Each film coated Tablet contains: Bisoprolol Fumarate IP 2.5 mg Telmisartan IP 40 mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt Ltd / M/s J.B. Chemicals & Pharmaceuticals Ltd. | 9.65 |
15 | Cefixime and Ofloxacin Oral suspension | Each 5ml reconstituted suspension contains: Cefixime IP as trihydrate eq. to Cefixime Anhydrous 50mg Ofloxacin IP 50mg | 1 ml | M/s Innova Captab Ltd. / M/s Emcure Pharmaceuticals Ltd. | 1.90 |
16 | Ibuprofen & Paracetamol Tablets | Each uncoated Tablet contains: Ibuprofen IP 400mg Paracetamol IP 325mg | 1 Tablet | M/s Prochem Pharmaceuticals Pvt. Ltd. / M/s Softdeal Pharmaceuticals Private Limited | 1.59 |
17 | Ranitidine Hydrochloride, Dicyclomine Hydrochloride & Activated Simethicone Tablet | Each film coated Tablet contains: Ranitidine Hydrochloride IP eq. to Ranitidine 150mg Dicyclomine Hydrochloride IP 10mg Activated Dimethicone IP (Simethicone) 20mg | 1 Tablet | M/s IndocoRemedies Limited | 2.09 |
18 | Telmisartan, Amlodipine & | Each film coated Tablet contains: | 1 Tablet | M/s Pure and Cure Healthcare Pvt. | 15.96 |
Sl. No. | Medicines | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Hydrochlorothia zide Tablets | Telmisartan IP 80mg, Amlodipine Besilate IP eq. to Amlodipine 5mg Hydrochlorothiazide IP 12.50mg | Ltd. / M/s Torrent Pharmaceuticals Ltd. | |||
19 | Telmisartan, Amlodipine & Hydrochlorothia zide Tablets | Each film coated Tablet contains: Telmisartan IP 40mg,Amlodipine Besilate IP eq. to Amlodipine 5mgHydrochlorothiazide IP 12.50mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Torrent Pharmaceuticals Ltd. | 10.45 |
20 | Ceftazidime and Avibactam (As Sodium Salt) powder for concentrate for solution for infusion | Each vial contains: Ceftazidime Pentahydrate (Sterile) eq. to Ceftazidime IP 2.0gm Avibactam Sodium (Sterile) eq. to Avibactam 0.5gm Sterile Sodium Carbonate IP (anhydrous) 232.9mg Sodium per vial content 6.44 mmol eq. to 148mg | 1 Vial | M/s Aqua Vitoe Laboratories / M/s Emcure Pharmaceuticals Limited | 1569.9 4 |
21 | Glimepiride & Metformin Hydrochloride (ER) Tablets | Each uncoated bilayered Tablet contains: Glimepiride IP 4mg Metformin Hydrochloride IP 500mg (In extended-release form) | 1 Tablet | M/s Innova Captab Ltd. / M/s Cadila Pharmaceuticals Ltd. | 11.28 |
22 | Glimepiride & Metformin Hydrochloride (ER) Tablets | Each uncoated bilayered Tablet contains: Glimepiride IP 3mg Metformin Hydrochloride IP 500mg (In extended-release form) | 1 Tablet | M/s Innova Captab Ltd. / M/s Cadila Pharmaceuticals Ltd. | 9.84 |
23 | Bilastine and Montelukast oral suspension | Each 5ml suspension contains: Bilastine 10mg Montelukast Sodium IP eq. to Monelukast 4mg | 1 ml | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Sun Pharmaceuticals Industries Limited | 1.72 |
24 | Aceclofenac, Paracetamol & Thiocolchicoside Tablets | Each film coated Tablet contains: Aceclofenac IP 100mg Paracetamol IP 325mg Thiocolchicoside IP 8mg | 1 Tablet | M/s Innova Captab Ltd. / M/s Mankind Pharma Ltd. | 25.98 |
25 | Aceclofenac, Paracetamol & Thiocolchicoside Tablets | Each film coated Tablet contains: Aceclofenac IP 100mg Paracetamol IP 325mg Thiocolchicoside IP 4mg | 1 Tablet | M/s Innova Captab Ltd. / M/s Mankind Pharma Ltd. | 18.05 |
26 | Hydrocortisone Acetate, Lidocaine, Zinc Oxide & | Each suppository contains: Hydrocortisone Acetate IP 0.25% w/w Lidocaine USP 3.0% w/w | 1 Supposi tory | M/s Bliss GVS Pharma Ltd. / M/s Zydus Healthcare Limited | 14.30 |
Sl. No. | Medicines | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Allantoin Suppositories | Zinc Oxide IP 5.0% w/w Allantoin IP 0.5% w/w | ||||
27 | Ciprofloxacin & Tinidazole Tablet | Each film coated Tablet contains: Ciprofloxacin Hydrochloride IP eq. to Ciprofloxacin 500mg Tinidazole IP 600mg | 1 Tablet | M/s Aagya Biotech Pvt. Ltd. / M/s J. B. Chemicals & Pharmaceuticals Ltd. | 10.64 |
28 | Fexofenadine Hydrochloride & Montelukast Tablet | Each film coated Tablet contains: Fexofenadine Hydrochloride IP 120mg Montelukast Sodium IP eq. to Montelukast 10mg | 1 Tablet | M/s Aagya Biotech Pvt. Ltd. / M/s J. B. Chemicals & Pharmaceuticals Ltd. | 15.10 |
29 | Antacid Antigas gel | Each 10ml (two teaspoonful) contains: Dried Aluminium Hydroxide Gel IP (added as paste) 830mg Magnesium Hydroxide IP (added as paste) 185mg Sodium Carboxymethylcellulose IP 100mg Simethicone IP 50mg | 1 ml | M/s Intas Pharmaceuticals Pvt. Ltd. | 0.56 |
30 | Bisoprolol Fumarate and Amlodipine Tablets | Each film coated Tablet contains: Bisoprolol Fumarate IP 2.5mg Amlodipine Besylate IP Eq. to Amlodipine 5mg | 1 Tablet | M/s Savi Health Science / M/s Alkem Laboratories Ltd. | 6.40 |
31 | Bisoprolol Fumarate and Amlodipine Tablets | Each film coated Tablet contains: Bisoprolol Fumarate IP 5mg Amlodipine Besylate IP Eq. to Amlodipine 5mg | 1 Tablet | M/s Savi Health Science / M/s Alkem Laboratories Ltd. | 8.98 |
32 | Atorvastatin, Clopidogrel & Aspirin Capsule | Each hard gelatine capsule contains: Atorvastatin Calcium IP eq. to Atorvastatin 40mg (As green coloured pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As two reddish brown coloured film coated Tablet, each containg 37.5mg Clopidogrel Tablets IP), Aspirin IP 75mg (As enteric coated white-coloured pellets) | 1 Capsule | M/s Windlas Biotech Limited / M/s Aristo Pharmaceuticals Pvt. Ltd. | 13.84 |
33 | Levocetirizine Dihydrochloride & Montelukast | Each 5ml contains: Levocetirizine Dihydrochloride IP 2.5mg | 1 ml | M/s Aagya Biotech / M/s J. B. Chemicals & | 1.47 |
Sl. No. | Medicines | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Sodium suspension | Montelukast Sodium IP eq. to Montelukast 4mg | Pharmaceuticals Ltd. | |||
34 | Linagliptin & Metformin Hydrochloride (ER) Tablets | Each film coated bilayered Tablet contains: Linagliptin 5mg Metformin Hydrochloride IP 500mg (as extended-release form) | 1 Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Mankind Pharma Limited | 12.86 |
35 | Pantoprazole & Domperidone Tablet | Each gastro-resistant Tablet contains: Pantoprazole Sodium IP (as sesquihydrate) eq. to Pantoprazole 40mg Domperidone IP 10mg | 1 Tablet | M/s Innova Captab Ltd. / Dr. Reddy's Laboratories Limited | 7.24 |
36 | Chlorphenirami ne Maleate, Dextromethorph an & Phenylephrine Syrup | Each 5ml contains: Chlorpheniramine Maleate IP 2mg Phenylephrine Hydrochloride IP 5mg Dextromethorphan Hydrobromide IP 10mg | 1 ml | M/s Stedman Pharmaceuticals Pvt. Ltd. | 1.02 |
37 | Cefixime and Ofloxacin Oral suspension | Each 5ml reconstituted suspension contains: Cefixime IP as trihydrate eq. to Cefixime Anhydrous 50mg Ofloxacin IP 50mg | 1 ml | M/s Innova Captab Ltd. / Dr. Reddy's Laboratories Limited | 1.90 |
The notification further added:
- The manufacturer of the above-mentioned formulations i.e., “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
- The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above-said table.
- The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from the date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- The above-mentioned retail price is applicable only to the individual manufacturer/marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
- In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
- Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.
To view the notice, click the link below:
Also Read: NPPA Fixes Retail Prices of 69 Formulations, Details
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd